All In Biotech

NDA 050782 · Bausch

Clindagel

Clindamycin Phosphate · Topical

Last checked: Nov 19, 2026Latest source record: Nov 27, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Nov 27, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

32,076

23,714 serious, 2,637 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2024.

CLINICAL STUDIES In one 12-week multicenter, randomized, evaluator-blind, vehicle-controlled, parallel comparison clinical trial in which patients used Clindamycin Phosphate Topical Gel, 1%, once daily or the vehicle gel once daily, in the treatment of acne vulgaris of mild to moderate severity, Clindamycin Phosphate Topical Gel applied once daily was more effective than the vehicle applied once daily. The mean percent reductions in lesion counts at the end of treatment in this study are shown in the following table: Lesions Clindamycin Phosphate Topical Gel QD N=162 Vehicle Gel QD N=82 Inflammatory 51% 40% P<0.05 Noninflammatory 25% 12% Total 38% 27% There was a trend in the investigator’s global assessment of the results, which favored Clindamycin Phosphate Topical Gel QD over the vehicle QD. In a contact sensitization study, four of the 200 subjects appeared to develop suggestive evidence of allergic contact sensitization to Clindamycin Phosphate Topical Gel. There was no signal for contact sensitization in the clinical trials under normal use conditions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLINDAGEL · CLINDAMYCIN PHOSPHATE EQ 1% BASE · GEL, TOPICAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,872
  • drug hypersensitivity2,561
  • diarrhoea2,110
  • rash1,927
  • nausea1,851
  • pain1,689
  • off label use1,582
  • fatigue1,462
  • acute kidney injury1,408
  • dyspnoea1,320
  • chronic kidney disease1,317
  • pyrexia1,311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004117
2005247
2006324
2007147
2008112
2009330
2010570
2011690
2012974
2013802
2014957
20151,402
20161,842
20172,059
20182,866
20193,728
20202,691
20212,416
20222,063
20232,447
20242,097
20251,856
20261,335

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clindagel (Clindamycin Phosphate)

2024 spending

$71K

Beneficiaries

12

33 claims

Per beneficiary

$5,903

$22.28 per unit

View as table
YearSpending
2020$472,867
2021$537,624
2022$408,784
2023$297,317
2024$70,836

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.